Project Grant K22AI179940
- The University of North Carolina at Chapel Hill received a $233,250 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) on May 13, 2025 to engineer non-replicating self-recirculating phages as a platform for gene therapy of the human microbiome. The project aims to develop methods that enable safe, efficient, and highly-targeted transduction of specific bacterial species within complex microbial...
- The University of North Carolina at Chapel Hill (UNC-CH) received a $498,885 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The grant, awarded on September 25, 2025, will support research to develop deep learning surrogate models that can predict the spread of antimalarial drug resistance, with a planned completion date of August 31, 2030. The research aims to...
- The University of North Carolina at Chapel Hill (UNC-CH) was awarded a $421,067 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on determining how neutrophil activities contribute to antibiotic treatment failure. The project aims to dissect the role of neutrophil extracellular traps (NETs) in promoting antibiotic tolerance in Staphylococcus aureus infections, evaluate...
- The University of North Carolina at Charlotte received a $413,542 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The funding supports research to develop novel non-immunostimulatory nanoparticle-carrier formulations that can deliver anti-inflammatory therapeutics or antimicrobial agents into resident central nervous system cells. The goal is to limit intracellular...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $521,030.00 to the University of North Carolina at Chapel Hill to conduct research on the role of phenotypic heterogeneity in the fitness of Clostridioides difficile, a leading cause of antibiotic-associated disease. The goal is to define the interplay between stochastic and regulatory mechanisms underlying the...
- This is a $300,892 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The grant supports research by the University of North Carolina at Chapel Hill to identify and annotate Rho, NusA, and NusG dependent transcriptional terminators in Clostridioides difficile. The objective is to determine how these factors regulate the expression of key virulence genes involved in C. difficile...
- This $427,625 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) with a period of performance from July 1, 2025 to June 30, 2027. The grant supports research at the University of North Carolina at Chapel Hill to elucidate the role of fimbriae (hair-like surface appendages) in Klebsiella pneumoniae-mediated liver abscess formation. The goal is to investigate the specific...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $240,060 to the University of North Carolina at Chapel Hill to conduct research on Vibrio cholerae biofilms. The goal is to identify the cellular states and spatial arrangement of different V. cholerae cell populations within biofilms, as well as the cellular changes that occur during biofilm dispersal. This...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,937,578 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of North Carolina at Chapel Hill. The grant, awarded on August 18, 2025, supports the development of an ACE2 immunodecoy therapy for long-lasting immunoprophylaxis against SARS-CoV-2 variants and other zoonotic coronaviruses that target the human ACE2 receptor. The project aims to optimize the linkage...
- This $427,625 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research focused on analyzing the ethical, legal, and social implications (ELSI) of genomic research on the human virome. The project aims to: 1) Integrate bioethics work with NIAID's viromics research to examine the ethical implications of this research, and 2) Address ELSI and policy issues that arise from the...
The University of North Carolina at Chapel Hill received a $162,000 Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) on August 22, 2025. The grant will fund research to understand the mechanisms and parameters controlling gene amplification leading to phenotypic heterogeneity in Enterobacter bacteria, which can contribute to antibiotic resistance. The research aims to characterize the principles of gene amplification that allow Enterobacter to develop resistant subpopulations, with the goal of informing new strategies to combat this type of antibiotic resistance. The project will be conducted at the University of North Carolina at Chapel Hill and is scheduled for completion by July 31, 2027.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 9/11/25 | ||
| Not listed | $162.0k | 8/22/25 |